Rezera Announces Late-Breaking Presentation of RESOLVE-1 Clinical Data at the American Heart Association (AHA) Scientific Sessions 2026BOSTON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Rezera Inc. (the “Company”), a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3 to address inflammatory drivers of cardiovascular and neurologic diseases, today announced that the recently completed RESOLVE-1 Phase 2 trial evaluating ruvonoflast in participants with elevated cardiometabolic risk has been accepted as a late-breaking Featured Science presentation at the American Heart Association (AHA) Scientific Sessions, taking place November 6-9 2026 in Chicago, Illinois.
Rezera Announces Plans to Launch the REVEAL-PAD Multi-Center Study Investigating the Role of Inflammation in Patients with Peripheral Artery DiseaseBOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Rezera Inc. (the “Company”), a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3 to address inflammatory drivers of cardiovascular and neurologic diseases, today announced plans to launch REVEAL-PAD, a prospective, multi-center observational study to investigate the role of inflammation in peripheral artery disease (PAD) and to identify patients who may be eligible to be screened for the Company’s planned Phase 3 trial of ruvonoflast in PAD.
Rezera Announces Ruvonoflast Met its Primary Inflammation Endpoint and Demonstrated Favorable Safety Profile in RESOLVE-1 Phase 2 Clinical TrialRezera has aligned with regulators on trial design of Phase 3 study of ruvonoflast in peripheral artery disease (PAD), expected to initiate in 1H of 2027
NodThera Inc. Changes Name to Rezera Inc. and Announces Ruvonoflast Phase 3 Development ProgramRezera plans to advance ruvonoflast into a Phase 3 clinical trial in peripheral artery disease (PAD) in H1 of 2027
